Table 2.

CCyR at 3, 6, and 12 months by therapy

	3 months				6 months				12 months
	Evaluable	CCyR	%	P	Evaluable	CCyR	%	P	Evaluable	CCyR	%	P
IM 400 mg	70	27	39		70	37	53		68	45	66
IM 800 mg	199	125	63	< .001	194	164	85	< .001	187	169	90	< .001
Second TKI	141	114	81		131	125	95		118	116	98

Evaluable indicates patients who received therapy and were evaluable for cytogenetic response at each time point; and IM, imatinib.